Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05386550
Title Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.